Center-Authored Papers

Filters: Author is Crawford, E David  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S et al..  2008.  Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(1):112-20. Abstract
Flaig TW, Tangen CM, Hussain MHA, Stadler WM, Raghavan D, Crawford DE, Glodé ML.  2008.  Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(9):1532-6. Abstract
Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford DE.  2008.  The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794.. The Journal of urology. 180(6):2453-7;discussion2458. Abstract
Sartor OA, Tangen CM, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford DE.  2008.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).. Cancer. 112(11):2393-400. Abstract
Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford DE.  2008.  Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.. Cancer. 112(10):2181-7. Abstract
2009
Lara PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford DE.  2009.  Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.. The Journal of urology. 181(2):512-6;discussion516-7. Abstract
Lippman SM, Klein EA, Goodman PJ, Lucia SM, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano MJ, Hartline JA et al..  2009.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA : the journal of the American Medical Association. 301(1):39-51. Abstract
Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford DE.  2009.  Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer.. Urologic oncology. 27(2):155-9. Abstract
Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, Abnet CC, Huang W-Y, Kibel AS, Crawford DE et al..  2009.  Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.. Carcinogenesis. 30(5):769-76. Abstract
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
Thompson IM, Tangen CM, Paradelo J, Lucia SM, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G et al..  2009.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.. The Journal of urology. 181(3):956-62. Abstract
deVere White RW, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MHA, Crawford DE.  2009.  A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).. The Journal of urology. 181(6):2476-80;discussion2480-1. Abstract
2011
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman BH, Wood DP, deVere White RW, Vogelzang NJ, Trump DL, Natale RB et al..  2011.  Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU international. 108(5):693-699. Abstract
Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF et al..  2011.  Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917.. Cancer prevention research (Philadelphia, Pa.). 4(11):1761-9. Abstract
Higano CS, Crawford DE.  2011.  New and emerging agents for the treatment of castration-resistant prostate cancer.. Urologic oncology. 29(6 Suppl):S1-8. Abstract
2012
Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford DE et al..  2012.  Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.. Urology. 79(3):633-7. Abstract
Tangen CM, Hussain MHA, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford DE, Vogelzang NJ et al..  2012.  Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346).. The Journal of urology. 188(4):1164-9. Abstract
2013
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford DE, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ et al..  2013.  Intermittent versus continuous androgen deprivation in prostate cancer.. The New England journal of medicine. 368(14):1314-25. Abstract
2014
Crawford DE, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger RE, Keane TE, Sieber P et al..  2014.  Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer.. Urology. Abstract
Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L et al..  2014.  Imputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.. Human molecular genetics. 23(24):6616-33. Abstract
25-Hydroxyvitamin D3 1-alpha-Hydroxylase
Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, Abnet CC, Huang W-Y, Kibel AS, Crawford DE et al..  2009.  Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.. Carcinogenesis. 30(5):769-76. Abstract
ADENOCARCINOMA
Flaig TW, Tangen CM, Hussain MHA, Stadler WM, Raghavan D, Crawford DE, Glodé ML.  2008.  Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(9):1532-6. Abstract
Sartor OA, Tangen CM, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford DE.  2008.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).. Cancer. 112(11):2393-400. Abstract
Adult
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
Flaig TW, Tangen CM, Hussain MHA, Stadler WM, Raghavan D, Crawford DE, Glodé ML.  2008.  Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(9):1532-6. Abstract